Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Rikke B. Holmgaard, Alexandra Brachfeld, Billel Gasmi, David R. Jones, Marissa Mattar, Thompson Doman, Mary Murphy, David Schaer, Jedd D. Wolchok & Taha Merghoub. (2016) Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. OncoImmunology 5:7.
Read now
Read now
Roberto Petrioli, Edoardo Francini, Anna Ida Fiaschi, Letizia Laera & Giandomenico Roviello. (2015) Targeted Therapies for Prostate Cancer. Cancer Investigation 33:7, pages 276-285.
Read now
Read now
Theresa L Whiteside. (2014) Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opinion on Biological Therapy 14:10, pages 1411-1425.
Read now
Read now
Brian Baldo. (2013) Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. OncoImmunology 2:10.
Read now
Read now
Alexei Shimanovsky, Ashif Jethava & Constantin A Dasanu. (2013) Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opinion on Biological Therapy 13:10, pages 1413-1427.
Read now
Read now
David M Lubaroff. (2012) Prostate cancer vaccines in clinical trials. Expert Review of Vaccines 11:7, pages 857-868.
Read now
Read now
Yan-Ho Cheng, Elissa W.P. Wong & C. Yan Cheng. (2011) Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis 1:3, pages 209-220.
Read now
Read now
Janice M. Reichert. (2011)
Antibody-based therapeutics to watch in 2011
. mAbs 3:1, pages 76-99.
Read now
Read now
Esther Erdei & Salina M Torres. (2010) A new understanding in the epidemiology of melanoma. Expert Review of Anticancer Therapy 10:11, pages 1811-1823.
Read now
Read now
Articles from other publishers (34)
Kewen He, David S. Hong, Chad Tang, Duygu Sezen, Livia Cox, Aurian Maleki, Genevieve Bertolet, Quynh-Nhu Nguyen, Nathan I. Comeaux, Lily Schuda, Dawei Chen & James W. Welsh. (2023) Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiotherapy and Oncology 183, pages 109618.
Crossref
Crossref
Jui-Ling Yu, Sophia R.-J. Jang & Kwei-Yan Liu. (2023) Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model. Cells 12:3, pages 507.
Crossref
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
489
540
.
Supriya Mandal, Waliza Ansar & Junaid Jibran Jawed. 2023. Viral, Parasitic, Bacterial, and Fungal Infections. Viral, Parasitic, Bacterial, and Fungal Infections
429
447
.
Roberta Coletti, Andrea Pugliese & Luca Marchetti. (2021) Modeling the effect of immunotherapies on human castration-resistant prostate cancer. Journal of Theoretical Biology 509, pages 110500.
Crossref
Crossref
Olivia Le Saux, Yasmine Lounici, Pauline Wajda, Sarah Barrin, Christophe Caux, Bertrand Dubois & Isabelle Ray-Coquard. (2021) Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. Critical Reviews in Oncology/Hematology 157, pages 103172.
Crossref
Crossref
Minfeng Yang, In Young Oh, Arpan Mahanty, Wei-Lin Jin & Jung Sun Yoo. (2020) Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. Cancers 12:9, pages 2334.
Crossref
Crossref
Yanfei Yang, Yang Yang, Jing Yang, Xia Zhao & Xiawei Wei. (2020) Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Christoforos Kosmidis, Konstantinos Sapalidis, Paul Zarogoulidis, Chrysanthi Sardeli, Charilaos Koulouris, Dimitrios Giannakidis, Efstathios Pavlidis, Athanasios Katsaounis, Nikolaos Michalopoulos, Stylianos Mantalobas, Georgios Koimtzis, Vyron Alexandrou, Theodora Tsiouda, Aikaterini Amaniti & Issak Kesisoglou. (2019) Inhaled Cisplatin for NSCLC: Facts and Results. International Journal of Molecular Sciences 20:8, pages 2005.
Crossref
Crossref
Giandomenico Roviello, Daniele Generali & Anna Ianza. (2019) Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue. Immunotherapy 11:5, pages 365-368.
Crossref
Crossref
Giandomenico Roviello, Fabrice Andre, Sergio Venturini, Barbara Pistilli, Giuseppe Curigliano, Massimo Cristofanilli, Pietro Rosellini & Daniele Generali. (2017) Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. European Journal of Cancer 86, pages 257-265.
Crossref
Crossref
Priyanka Khanna, Normand Blais, Pierre-Olivier Gaudreau & Luis Corrales-Rodriguez. (2017) Immunotherapy Comes of Age in Lung Cancer. Clinical Lung Cancer 18:1, pages 13-22.
Crossref
Crossref
Grzegorz Stasiłojć, Anders Österborg, Anna M. Blom & Marcin Okrój. (2016) New perspectives on complement mediated immunotherapy. Cancer Treatment Reviews 45, pages 68-75.
Crossref
Crossref
Elly Marcq, Patrick Pauwels, Jan P. van Meerbeeck & Evelien L.J. Smits. (2015) Targeting immune checkpoints: New opportunity for mesothelioma treatment?. Cancer Treatment Reviews 41:10, pages 914-924.
Crossref
Crossref
Matthias Preusser, Michael Lim, David A. Hafler, David A. Reardon & John H. Sampson. (2015) Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology 11:9, pages 504-514.
Crossref
Crossref
Angelo Di Leo, Giuseppe Curigliano, Véronique Diéras, Luca Malorni, Christos Sotiriou, Charles Swanton, Alastair Thompson, Andrew Tutt & Martine Piccart. (2015) New approaches for improving outcomes in breast cancer in Europe. The Breast 24:4, pages 321-330.
Crossref
Crossref
T. Stahl & C. Loquai. (2015) Therapienebenwirkungen und Nachsorge bei malignem MelanomTreatment side effects and follow-up of malignant melanoma. Der Radiologe 55:2, pages 136-144.
Crossref
Crossref
Charlotte Welinder, Göran Jönsson, Christian Ingvar, Lotta Lundgren, Bo Baldetorp, Håkan Olsson, Thomas Breslin, Melinda Rezeli, Bo Jansson, Thomas Laurell, Thomas E. Fehniger, Elisabet Wieslander, Krzysztof Pawlowski & György Marko-Varga. (2014) Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification. Journal of Proteome Research 13:3, pages 1315-1326.
Crossref
Crossref
Antonio M. Grimaldi, Pamela B. Cassidy, Sancy Leachmann & Paolo A. Ascierto. 2014. Advances in Nutrition and Cancer. Advances in Nutrition and Cancer
443
455
.
Jedd D. Wolchok, F. Stephen Hodi, Jeffrey S. Weber, James P. Allison, Walter J. Urba, Caroline Robert, Steven J. O'Day, Axel Hoos, Rachel Humphrey, David M. Berman, Nils Lonberg & Alan J. Korman. (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences 1291:1, pages 1-13.
Crossref
Crossref
Stéphane Oudard. (2013) Progress in emerging therapies for advanced prostate cancer. Cancer Treatment Reviews 39:3, pages 275-289.
Crossref
Crossref
J Bastid, A Cottalorda-Regairaz, G Alberici, N Bonnefoy, J-F Eliaou & A Bensussan. (2012) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32:14, pages 1743-1751.
Crossref
Crossref
Alice Hervieu, Cédric Rébé, Frédérique Végran, Fanny Chalmin, Mélanie Bruchard, Pierre Vabres, Lionel Apetoh, François Ghiringhelli & Grégoire Mignot. (2013) Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. Journal of Investigative Dermatology 133:2, pages 499-508.
Crossref
Crossref
Dirk Schadendorf, Corinna Kochs & Elisabeth LivingstoneDirk Schadendorf, Corinna Kochs & Elisabeth Livingstone. 2013. Handbook of Cutaneous Melanoma. Handbook of Cutaneous Melanoma
79
104
.
Flavie Bompaire, Christine Mateus, Hervé Taillia, Thierry De Greslan, Marion Lahutte, Magali Sallansonnet-Froment, Madani Ouologuem, Jean-Luc Renard, Guy Gorochov, Caroline Robert & Damien Ricard. (2012) Severe meningo-radiculo-nevritis associated with ipilimumab. Investigational New Drugs 30:6, pages 2407-2410.
Crossref
Crossref
J D Dias, O Hemminki, I Diaconu, M Hirvinen, A Bonetti, K Guse, S Escutenaire, A Kanerva, S Pesonen, A Löskog, V Cerullo & A Hemminki. (2011) Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Therapy 19:10, pages 988-998.
Crossref
Crossref
J. Harrison Howard, John F. Thompson, Nicola Mozzillo, Omgo E. Nieweg, Harald J. Hoekstra, Daniel F. Roses, Vernon K. Sondak, Douglas S. Reintgen, Mohammed Kashani-Sabet, Constantine P. Karakousis, Brendon J. Coventry, William G. Kraybill, B. Mark Smithers, Robert Elashoff, Stacey L. Stern, Alistair J. Cochran, Mark B. Faries & Donald L. Morton. (2012) Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). Annals of Surgical Oncology 19:8, pages 2547-2555.
Crossref
Crossref
Licun Wu, Zhihong Yun, Tetsuzo Tagawa, Katrina Rey-McIntyre & Marc de Perrot. (2012) CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma. Molecular Cancer Therapeutics 11:8, pages 1809-1819.
Crossref
Crossref
Rui-Ru Ji, Scott D. Chasalow, Lisu Wang, Omid Hamid, Henrik Schmidt, John Cogswell, Suresh Alaparthy, David Berman, Maria Jure-Kunkel, Nathan O. Siemers, Jeffrey R. Jackson & Vafa Shahabi. (2011) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology, Immunotherapy 61:7, pages 1019-1031.
Crossref
Crossref
Grazia Graziani, Lucio Tentori & Pierluigi Navarra. (2012) Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacological Research 65:1, pages 9-22.
Crossref
Crossref
Frances A. Shepherd, Jean-Yves Douillard & George R. BlumenscheinJr.Jr.. (2011) Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome. Journal of Thoracic Oncology 6:10, pages 1763-1773.
Crossref
Crossref
Genevieve M. Weir, Robert S. Liwski & Marc Mansour. (2011) Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines. Cancers 3:3, pages 3114-3142.
Crossref
Crossref
Nicole Joller, Jason P. Hafler, Boel Brynedal, Nasim Kassam, Silvia Spoerl, Steven D. Levin, Arlene H. Sharpe & Vijay K. Kuchroo. (2011) Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. The Journal of Immunology 186:3, pages 1338-1342.
Crossref
Crossref
Vishal Patel, Hardik Gandhi & Aman Upaganlawar. (2011) Ipilimumab: Melanoma and beyond. Journal of Pharmacy And Bioallied Sciences 3:4, pages 546.
Crossref
Crossref